No abstract

This case report documents 20 patients suffering from uncontrolled type 2 diabetes mellitus, presenting complaints of fluctuating blood glucose levels. The parameters like fasting and postprandial blood glucose, HbA1c and C- peptide levels of patients were evaluated. These patients were then advised an adjuvant therapy of Gplife advanced diabetic support tablets along with their daily insulin injections. After 60 days of treatment, the therapy was discontinued, and patients were subjected to continuous glucose monitoring for 8 days and time in range (TIR) percentage was calculated. Also, the fasting and postprandial blood glucose, HbA1c and C-peptide levels were estimated. The average TIR percentage was found to be 93.2%, whereas the time above range (TAR) and time below range (TBR) was 6.8 % and 0 % respectively, which indicates that the patients had a negligible incidence of hyper and hypoglycemia after 60 days of treatment. There was a significant decrease by 61 % in HbA1c levels, 40.05 % in fasting blood glucose levels and 34.29 % in postprandial blood glucose levels (p<0.001). C-peptide levels increased by 1.38 folds after 60 days of treatment. Also, there were no evidence of diabetic comorbidities. Thus, indicating a marked improvement in the diabetic condition and overall quality of life in patients.

Type I or Type II diabetes, once recognized as juvenile diabetes or insulin-dependent diabetes, is a chronic illness in which the pancreas produces slight or no insulin. Insulin-dependent diabetes is a syndrome of glucose homeostasis considered by autoimmune destruction of the insulin-producing pancreatic Beta-cell that gradually leads to insulin deficiency. As there is no perfect treatment for management, Gplife has thought of and developed a product that is found to be effective in the management of insulin-dependent diabetes. After 60 days of evaluation of cases, it is observed that fasting blood glucose was reduced by 62.25%, postprandial glucose levels were reduced by 62.37%, HBA1C levels were reduced by 39.57%, C Peptide levels were increased by 26.67%, also the external insulin injection requirement of the patient’s decreased by 88.57%. This case study gives an overview of the current understanding of the disease and the efficacy of advance diabetic support products in insulin-dependent diabetes. It is evident that the said product further helps to reduce insulin and OHA doses for the management of insulin-dependent diabetes. It is suggested that the advance diabetes support product should be further extensively used as a monotherapy or adjunctive therapy for the regulation, or management or control of insulin-dependent diabetes.

Introduction: Ayurvedic medications are extensively used across the world for illness prevention and treatment. The active ingredients of Coroprotect dry syrup are Jethimadh ext, Ajma ext., Tulsi ext., Pipper ext., Sunth ext., Kalamari ext., Vasa ext., Taj ext., Lavang ext., Nagarvel ext., Haridra ext., Kakamachi ext., Pushkarmool ext., and Phudina ful, etc. Because there is no scientific proof that this formulation is safe, a comprehensive toxicity study in wistar rats was conducted. Objective: In Rodents, acute and subacute toxicity of coroprotect dry syrup was studied after a single and repeated 28-day oral dosage Administration. Method: Six Wistar female rats were given a single dose of coroprotect dry syrup at 2000 mg/kg by oral gavage, while doses of 100, 200 and 500 mg/kg/day were given over the course of 28 days in a repeated-dose subacute toxicity study. Results: In an acute toxicity investigation involving coroprotect dry syrup administration, no therapies fatalities or toxic symptoms were found. In the repeated dosage study, there were no substantial differences in body weight fluctuations, food/water ingestion, hematology, or clinical biochemistry content among the control as well as coroprotect dry syrup groups. There were no gross pathological abnormalities or variations in relative organ weights between the control and coroprotect dry syrup groups. Histopathological investigation revealed no abnormalities after therapy with coroprotect dry syrup. Conclusion: In a repeated dosage toxicity study in rodents, the coroprotect dry syrup was determined to be safe at all dose levels.

Aim: Diabetes support product (ADSP) with phytocompounds was proposed to improve insulin secretion, avoid pancreatic beta cell apoptosis, and moderate beta cell differentiation and proliferation. In this research work, beta cell regenerative potential of ADSP was evaluated with STZ induced diabetes in rodents. Method: Single dose of Streptozotocin (STZ) (70mpk; i.p.) was used to induce diabetes in the Wistar rats. The treatment of vehicle or test or GLB was continued for the next 28 days to assess sub-acute anti-diabetic potential. Fasting blood glucose levels (BGL) was monitored weekly once throughout the experiment. Bodyweight, Feed-water consumption was calculated on every day till end of the experiment. Interleukin-6, Interleukin-1β and Interferon-γ was also analysis from blood serum after 28 days of treatment in rats. Further, animal was humanely sacrifice and organs such as liver, kidney(s) and pancreas were isolated for histopathology analysis. Result: Research showed that Insulin is Increased by 3 times in comparison with the diabetic group by ADSP after 28 days. After 28 days treatment of ADSP to rodents, Interleukin-6 decreased by 52%, Interleukin-1β decreased by 73% and Interferon-γ decreased by 28% in comparison with the diabetic control group. It is also observed in histopathology studies that there was a rise in the quantity of islets after 28 days treatment of ADSP in Streptozotocin carried diabetic rats. Conclusion: Hence in conclusion, advance diabetes support product supposed to be appreciated as synergistic product of encouraging the β-cell regeneration in vivo.